$599

Verily Launches CVRM Virtual Care Program; Sanders Questions Novo Drug Pricing; Farxiga Receives Pediatric Approval in US

Three cardiometabolic-related news items have been observed: Verily launched a new AI-powered CVRM virtual care program (view press release); Bernie Sanders is moving to subpoena Novo Nordisk surrounding Wegovy and Ozempic prices (view article); and FDA approved the Farxiga pediatric T2DM indication (view press release). Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here